- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00737516
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
June 12, 2013 updated by: National Marrow Donor Program
A Centralized Cord Blood Registry to Facilitate Allogeneic, Unrelated Donor Umbilical Cord Blood Transplantation
The National Marrow Donor Program (NMDP) has established a system for registering, matching, and tracking unrelated donor cord blood units (CBUs) and transplant outcomes.
Study subjects are donors who enroll through collaborating cord blood banks.
This study creates uniform collection, screening, testing and storage requirements for cord blood units.
The purpose of standardization is to improve efficiency in the selection of cord blood units for transplantation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The NMDP Cord Blood registry is organized as a network of member cord blood banks and transplant centers whose interactions are managed by the NMDP's Center for Cord Blood.
Banks agree to comply with uniform collection, screening, testing and storage requirements.
Upon approval of membership, cord blood banks submit detailed information on each stored CBU for registration into a proprietary computer system.
A transplant center, working on behalf of potential recipients, submits search requests to the NMDP and receives electronic reports detailing potentially suitable CBUs.
From these reports, the transplant center selects a CBU(s) for further testing, which includes at a minimum confirmation of the CBUs Human Leukocyte Antigen (HLA) typing data.
Upon final selection of the desired CBU for transplantation, arrangements are made for timely shipment of the unit to the transplant center.
Following transplantation, recipient outcome data are submitted by the transplant center for addition to the study database.
Study Type
Interventional
Enrollment (Actual)
3621
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Covina, California, United States, 91722
- StemCyte International Cord Blood Center
-
Orange, California, United States, 92868
- Children's Hospital of Orange County Cord Blood Bank
-
San Diego, California, United States, 92103
- Ashley Ross Cord Blood Program
-
-
Colorado
-
Aurora, Colorado, United States, 80218
- University of Colorado Cord Blood Bank
-
Denver, Colorado, United States, 80230
- Bonfils Cord Blood Service
-
-
Florida
-
Altamonte Springs, Florida, United States, 32701
- Lifeforce Cryobanks
-
Boca Raton, Florida, United States, 33431
- Gift of Life Marrow Foundation
-
Gainesville, Florida, United States, 32607
- LifeCord
-
-
Illinois
-
Glenview, Illinois, United States, 60025
- ITxM Cord Blood Services
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- J.P. McMarthy Cord Stem Cell Bank
-
Grand Rapids, Michigan, United States, 49503
- Michigan Community Blood Centers
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- St. Louis Cord Blood Bank
-
-
New Jersey
-
Allendale, New Jersey, United States, 07401
- CBS - New Jersey Cord Blood bank
-
Camden, New Jersey, United States, 08103
- Coriell - New Jersey Cord Blood Bank
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Carolinas Cord Blood Bank
-
-
Ohio
-
Cleveland, Ohio, United States, 44128
- Cleveland Cord Blood Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M.D. Anderson Cord Blood Bank
-
San Antonio, Texas, United States, 78201
- Texas Cord Blood Bank
-
-
Washington
-
Seattle, Washington, United States, 98104
- Puget Sound Blood Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Pregnancy
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: single arm
HPC, Cord Blood
|
Search for HLA compatible cord blood units using the NMDP registry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Study safety and efficacy for treatment for malignant and non-malignant disorders
Time Frame: annually
|
annually
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Study relationship between HLA disparity and survival
Time Frame: annually
|
annually
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John P Miller, M.D., Ph.D., National Marrow Donor Program
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2000
Primary Completion (ACTUAL)
October 1, 2011
Study Completion (ACTUAL)
October 1, 2011
Study Registration Dates
First Submitted
August 15, 2008
First Submitted That Met QC Criteria
August 18, 2008
First Posted (ESTIMATE)
August 19, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
June 21, 2013
Last Update Submitted That Met QC Criteria
June 12, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T00004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Ruijin HospitalThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsNot yet recruitingLymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Reid Merryman, MDBeiGene; GenmabRecruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Refractory Lymphoma | Relapsed LymphomaUnited States
-
BeiGeneCompletedFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone LymphomaChina
Clinical Trials on HPC, Cord Blood
-
BHI Therapeutic SciencesUnknownAcute Ischemic StrokeUnited States
-
Andrei KrassioukovUniversity of British Columbia; Coloplast A/S; Vancouver Coastal Health; International...CompletedSpinal Cord Injuries | Neurogenic Lower Urinary Tract DysfunctionCanada
-
MinYoung Kim, M.D.Completed
-
Bundang CHA HospitalWithdrawnCerebral PalsyKorea, Republic of
-
Bundang CHA HospitalWithdrawn
-
MinYoung Kim, M.D.CompletedGlobal Developmental DelayKorea, Republic of
-
MinYoung Kim, M.D.Completed
-
MinYoung Kim, M.D.CHA UniversityCompletedGlobal Developmental DelayKorea, Republic of
-
Kaplan Medical CenterRecruitingNeutropenia (Low White Blood Cell Count)Israel